Get to know our clinical trials
Clinical trial to compare the efficacy and safety of masitinib and placebo in the treatment of patients with severe indolent or latent systemic mastocytosis with disability, unresponsive to optimal symptomatic treatment.
THE OBJECTIVE OF THIS STUDY IS TO COMPARE THE EFFICACY AND SAFETY OF AN EXPERIMENTAL DRUG, MASITINIB, ADMINISTERED ORALLY AT 3 MG/KG/DAY WITH A SWITCH AFTER 4 WEEKS OF TREATMENT TO 4.5 MG/KG/DAY AND ANOTHER SWITCH AFTER 4 WEEKS OF TREATMENT TO 6 MG/KG/DAY (ALL SWITCHES WILL BE SUBJECT TO TOXICITY MONITORING) VERSUS PLACEBO IN THE TREATMENT OF PATIENTS WITH SEVERE INDOLENT OR LATENT SYSTEMIC MASTOCYTOSIS WITH DISABILITY, UNRESPONSIVE TO SYMPTOMATIC TREATMENT. MASITINIB WILL BE TAKEN TWICE DAILY ORALLY.
Technical Summary
- PHASE III, PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED (1:1 RANDOMIZATION), PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE-BLIND STUDY WITH A DURATION OF 24 WEEKS WITH THE POSSIBILITY OF EXTENSION TO COMPARE THE EFFICACY AND SAFETY OF MASITINIB AND PLACEBO IN THE TREATMENT OF PATIENTS WITH SEVERE INDOLENT OR LATENT SYSTEMIC MASTOCYTOSIS WITH DISABILITY, UNRESPONSIVE TO OPTIMAL SYMPTOMATIC TREATMENT.
- Code EudraCT: 2016-001447-39
- Protocol number: AB15003
- Promoter: AB Science
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.